Mounjaro Stomach Paralysis Lawsuit | 2026 Latest Updates

Lawsuits allege that Mounjaro, the diabetes drug from Eli Lilly, caused stomach paralysis and other serious stomach and bowel injuries. Plaintiffs also say the drug makers did not adequately warn of the risk. The claims are pending in federal MDL No. 3094 in the Eastern District of Pennsylvania. Eli Lilly and Novo Nordisk are defendants. The newest order, from August 28, 2026, set the schedule for the expert hearing on warnings and causation. The first suit naming Mounjaro was filed on August 2, 2023. No settlement, verdict or recall of Mounjaro has been announced.

Latest Mounjaro Stomach Paralysis Lawsuit Updates

August 28, 2026: Court Issues Rule 702 Scheduling Order

The U.S. District Court for the Eastern District of Pennsylvania issued a scheduling order for the Rule 702 evidentiary (“Daubert”) hearing on Cross Cutting Issues 2 and 3 in MDL 3094 [1]. No trial date has been set.

April 30, 2026: Court Sets September Rule 702 Hearing

Judge Marston signed Case Management Order No. 32, the Fifth Amended Scheduling Order for the issues of warnings and causation [2]. It set the Rule 702 hearing for September 10-18, 2026, in Courtroom 16B. Rule 702 and summary judgment motions were due May 19, 2026. Briefing on those motions ran through August 7, 2026. The hearing days start at 9:00 a.m.

January 14, 2026: Court Creates a Streamlined Docket

Case Management Order No. 30 created a second, streamlined docket for the MDL, numbered 01-md-3094 [3]. The court found it would bring clarity and efficiency in running the MDL. The new docket holds the transfer order, master pleadings and case management orders. It also holds rulings on discovery, dispositive and Rule 702 motions.

October 3, 2025: Court Adopts Short Form Complaint

Case Management Order No. 27 is the Short Form Complaint Enabling Order. It made the Master Complaint together with a Short Form Complaint each plaintiff’s operative complaint in the MDL [4]. The order states that the Master Complaint is not intended to consolidate or merge the plaintiffs’ claims. It was entered as Document 503 on the MDL docket.

August 15, 2025: Court Rules on Gastroparesis Diagnosis

Judge Marston issued an opinion on Cross Cutting Issue 1 that excluded the plaintiffs’ experts, Dr. Daniel Raines and Dr. Eliot Siegel, on diagnosing gastroparesis without a gastric emptying study [5]. The opinion is Document 467 on the MDL docket. It rules on expert evidence and is not a finding that the drugs cause gastroparesis.

December 12, 2024: JPML Order Adds Saxenda Case

The Judicial Panel on Multidistrict Litigation transferred a Saxenda case, a Novo Nordisk drug, into MDL 3094 in its transfer order, Document 272 [6]. The order states that the initial centralization covered five products: Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro. Eli Lilly makes Trulicity and Mounjaro.

August 2, 2023: First Mounjaro Lawsuit Is Filed

A Louisiana woman sued Novo Nordisk and Eli Lilly, alleging Ozempic and Mounjaro cause gastrointestinal injury. NBC News reported it as the first such lawsuit [7]. The federal MDL followed in 2024.

What Is Gastroparesis?

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), gastroparesis is also called delayed gastric emptying. It slows or stops the movement of food from your stomach to your small intestine [8]. When you have gastroparesis, your stomach muscles work poorly or not at all, and your stomach takes too long to empty its contents. News coverage of the Mounjaro claims calls this condition stomach paralysis.

Who May Be Affected?

The claims cover people prescribed Mounjaro who developed gastroparesis, ileus, intestinal obstruction or another gastrointestinal injury, as the JPML order describes them. The Mounjaro prescribing information from Lilly says the drug is prescribed to adults and to children 10 years of age and older who have type 2 diabetes [9]. Under the court’s August 15, 2025 ruling, a plaintiff claiming drug-induced gastroparesis must have had a gastric emptying study at diagnosis that confirmed delayed emptying. The same MDL covers Ozempic and Wegovy claims. See our Ozempic stomach paralysis lawsuit and Wegovy stomach paralysis lawsuit pages. According to the JPML pending MDL report, 3,763 actions were pending in MDL 3094 on June 1, 2026 [10]. Whether any one person qualifies depends on an individual legal review of their records.

Reported Injuries or Damages

The court’s October 17, 2024 memorandum says each plaintiff claims gastrointestinal symptoms or injuries after taking a GLP-1 drug. These include cholecystitis and severe nausea and vomiting [11]. The court limited the MDL to gastrointestinal injury cases. The first Mounjaro suit alleged severe vomiting, gastrointestinal burning, hospitalization for stomach pain and lost teeth, according to USA Today [12]. It sought compensatory and punitive damages. Those are allegations. The suit did not say the plaintiff was diagnosed with gastroparesis. Her attorney told NBC News she had not been diagnosed. No court has found that the drugs caused these injuries. An outside physician told NBC News the problem could also come from another illness or from diabetes. An FDA spokesperson said in August 2023 that it is unclear whether GLP-1 medications contribute to gastroparesis. A 2019 Gut review by Mayo Clinic authors lists the main symptoms of gastroparesis as fullness, early satiety, nausea, vomiting and bloating [13]. NIDDK also lists dehydration from repeated vomiting and malnutrition as possible complications of gastroparesis, the condition at the center of these claims.

Recall and Regulatory Background

The FDA has announced no recall of Mounjaro [14]. Lilly’s label, revised in August 2026, says Mounjaro use has been associated with gastrointestinal adverse reactions, sometimes severe. It says Mounjaro is not recommended in patients with severe gastroparesis.

Evidence to Preserve

Keep records that show what you took, when you took it and what happened afterward:

• Prescription and pharmacy records that show your dose, start date and any dose change.
• Hospital, emergency room and doctor records from each visit for vomiting, pain or other stomach and bowel problems.
• Results of any gastric emptying study, endoscopy or imaging test, with the date of each.
• A dated symptom diary covering vomiting, nausea, fullness, pain and any change in weight.
• Medication names, lot or pen details if you kept them, and photos of the pens and packaging.
• Receipts and bills for out-of-pocket medical costs, kept with the matching visit records.
• Messages with your doctors, pharmacy or the manufacturer about Mounjaro and your symptoms.

Filing Deadlines

Deadlines for filing a claim come from state law and vary with where you live and when the injury happened. In some states the clock starts at diagnosis. Missing a deadline can end a claim, even one built on strong facts. Check with a lawyer promptly so you know which deadline applies to your situation and how much time is left.

Frequently Asked Questions

Can Mounjaro Cause Stomach Paralysis?

Whether Mounjaro can cause stomach paralysis has not been decided. Lilly’s label says tirzepatide delays gastric emptying. Plaintiffs allege it caused gastroparesis, and general causation is still a pending question before the court.

What Does the Research Say About Mounjaro and Gastroparesis?

The research on Mounjaro and gastroparesis includes Lilly’s label, which reports severe gastrointestinal adverse reactions in placebo-controlled trials. They occurred more frequently on Mounjaro (1.3% on 5 mg, 0.4% on 10 mg, 1.2% on 15 mg) than on placebo (0.9%).

What Issues Is the Court Deciding in the Mounjaro Stomach Paralysis Lawsuit?

The court framed three cross cutting issues in the Mounjaro stomach paralysis lawsuit, as the defendants put them: gastroparesis diagnostic testing, preemption and adequacy of warnings, and general causation. It has ruled on the first. The Rule 702 hearing covers the other two.

How Did the Gastric Emptying Ruling Affect the Lawsuits?

The gastric emptying ruling will have “relatively little effect on the vast majority of the cases,” the court said, because most plaintiffs claim permanent or persistent gastroparesis. It added that some plaintiffs “will be unable to prove that they suffered from gastroparesis.”

Who Is More Likely to Get Gastroparesis?

NIDDK says people are more likely to get gastroparesis if they have diabetes. The same goes for surgery on the esophagus, stomach or small intestine, and certain cancer treatments such as radiation to the chest or stomach area. These are background risk factors only.

Are Vision Loss Claims Part of the Mounjaro Stomach Paralysis Lawsuit?

No, vision loss claims are not part of the Mounjaro stomach paralysis lawsuit. According to the JPML, a separate MDL, No. 3163, covers GLP-1 non-arteritic anterior ischemic optic neuropathy cases, which involve vision.

References

1. https://www.paed.uscourts.gov/mdl/mdl3094/orders
2. https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/24md3094_cm-ord_32.pdf
3. https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/24md3094_cm-ord_30.pdf
4. https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/24md3094_cm-ord_27.pdf
5. https://assets.alm.com/49/40/6783287f42c0938c3e0887e31822/opinion-on-issue-1-rule-702-motions-8-15-2025.pdf
6. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3094-Transfer_Order-12-24.pdf
7. https://www.nbcnews.com/health/health-news/makers-ozempic-mounjaro-sued-stomach-paralysis-claims-rcna97819
8. https://www.niddk.nih.gov/health-information/digestive-diseases/gastroparesis/definition-facts
9. https://pi.lilly.com/us/mounjaro-uspi.pdf
10. https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-June-1-2026.pdf
11. https://www.govinfo.gov/content/pkg/USCOURTS-paed-2_24-md-03094/pdf/USCOURTS-paed-2_24-md-03094-0.pdf
12. https://www.usatoday.com/story/news/health/2023/08/09/ozempic-moujaro-weight-loss-drug-makers-patient-lawsuit/70555199007/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6874806/
14. https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls